PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing